MedTrace Logo

Phase 1a/1b BGB-290 for Advanced Solid Tumors.

NCT02361723 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 101

Last updated 2024-12-27

No results posted yet for this study

Summary

The study contains Phase 1A and Phase 1B. Phase 1A has Part1 (BID Dose Escalation) and Part2 (QD Dosing Escalation) Evaluation of a cohort of at least three participants completing one cycle of treatment at that dose level and dose regimen is required prior to determining the next dose level and dose regimen for the next cohort. Phase 1B has PartA (BID Dosing Expansion) will investigate efficacy in participants with selected tumor types and further evaluate safety and tolerability of BGB 290 at recommended dose for future studies. and PartB (Food Effect) will investigate the food effect on the Pharmacokinetics (PK) of BGB 290 in participants with advanced solid tumors.

Conditions

  • For Participants With Advanced Solid Tumors Failed With Previous Lines of Treatment

Interventions

DRUG

BGB-290

DRUG

BGB-290

DRUG

BGB-290

DRUG

BGB-290

DRUG

BGB-290

Sponsors & Collaborators

  • BeiGene

    lead INDUSTRY

Principal Investigators

  • Michael Millward, MD · Linear Clinical Research

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-07-03
Primary Completion
2019-09-03
Completion
2019-09-03

Countries

  • Australia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02361723 on ClinicalTrials.gov